SG11201900096QA - Novel processes for preparation of soluble guanylate cyclase stimulators - Google Patents

Novel processes for preparation of soluble guanylate cyclase stimulators

Info

Publication number
SG11201900096QA
SG11201900096QA SG11201900096QA SG11201900096QA SG11201900096QA SG 11201900096Q A SG11201900096Q A SG 11201900096QA SG 11201900096Q A SG11201900096Q A SG 11201900096QA SG 11201900096Q A SG11201900096Q A SG 11201900096QA SG 11201900096Q A SG11201900096Q A SG 11201900096QA
Authority
SG
Singapore
Prior art keywords
international
preparation
massachusetts
pct
guanylate cyclase
Prior art date
Application number
SG11201900096QA
Other languages
English (en)
Inventor
Song Xue
Vishnu Vardhan Reddy Karnati
Robert C Livingston
Original Assignee
Ironwood Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ironwood Pharmaceuticals Inc filed Critical Ironwood Pharmaceuticals Inc
Publication of SG11201900096QA publication Critical patent/SG11201900096QA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11201900096QA 2016-07-07 2017-07-06 Novel processes for preparation of soluble guanylate cyclase stimulators SG11201900096QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662359453P 2016-07-07 2016-07-07
PCT/US2017/040810 WO2018009597A1 (en) 2016-07-07 2017-07-06 Novel processes for preparation of soluble guanylate cyclase stimulators

Publications (1)

Publication Number Publication Date
SG11201900096QA true SG11201900096QA (en) 2019-02-27

Family

ID=59416789

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201900096QA SG11201900096QA (en) 2016-07-07 2017-07-06 Novel processes for preparation of soluble guanylate cyclase stimulators

Country Status (16)

Country Link
US (4) US11319308B2 (https=)
EP (2) EP4249488A3 (https=)
JP (1) JP7112384B2 (https=)
KR (1) KR102487872B1 (https=)
CN (2) CN109563077B (https=)
AU (1) AU2017291827B2 (https=)
BR (1) BR112019000291A2 (https=)
CA (1) CA3029375A1 (https=)
CL (2) CL2019000016A1 (https=)
EA (1) EA201990237A1 (https=)
ES (1) ES2963563T3 (https=)
IL (1) IL263995B (https=)
MA (1) MA45603A (https=)
MX (2) MX389920B (https=)
SG (1) SG11201900096QA (https=)
WO (1) WO2018009597A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109563086B (zh) 2016-07-07 2023-05-23 赛克里翁治疗有限公司 用于制备可溶性鸟苷酸环化酶刺激剂的方法
CN109563077B (zh) 2016-07-07 2026-03-10 赛克里翁治疗有限公司 用于制备可溶性鸟苷酸环化酶刺激剂的新方法
US11274096B2 (en) 2018-01-10 2022-03-15 Cyclerion Therapeutics, Inc. Processes and intermediates for the preparation of soluble guanylate cyclase stimulators
WO2019161534A1 (en) * 2018-02-22 2019-08-29 Ironwood Pharmaceuticals, Inc. Novel processes and intermediates for preparation of soluble guanylate cyclase stimulators

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8969349B2 (en) * 2010-05-26 2015-03-03 Sunovion Pharmaceuticals Inc. Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors
EP2588465B1 (en) 2010-06-30 2017-01-25 Ironwood Pharmaceuticals, Inc. Sgc stimulators
CN106117194A (zh) * 2011-12-27 2016-11-16 铁木医药有限公司 可用作sgc刺激剂的2‑苄基、3‑(嘧啶‑2‑基)取代的吡唑类
EP2897953B8 (en) * 2012-09-19 2019-06-26 Cyclerion Therapeutics, Inc. Sgc stimulators
EA033168B1 (ru) 2013-03-15 2019-09-30 Сайклерион Терапьютикс, Инк. СТИМУЛЯТОРЫ sGC
CA2933250A1 (en) 2013-12-11 2015-06-18 Ironwood Pharmaceuticals, Inc. Sgc stimulators
EP3194386A2 (en) * 2014-09-17 2017-07-26 Ironwood Pharmaceuticals, Inc. Sgc stimulators
EP3194382B1 (en) * 2014-09-17 2021-09-08 Cyclerion Therapeutics, Inc. Pyrazole derivatives as sgc stimulators
EA201790627A1 (ru) * 2014-09-17 2017-09-29 Айронвуд Фармасьютикалз, Инк. СТИМУЛЯТОРЫ рГЦ
US20170298055A1 (en) * 2014-09-17 2017-10-19 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
CA3006746C (en) * 2015-11-30 2024-01-30 Ironwood Pharmaceuticals, Inc. Solid dispersions comprising a sgc stimulator
CN109563086B (zh) * 2016-07-07 2023-05-23 赛克里翁治疗有限公司 用于制备可溶性鸟苷酸环化酶刺激剂的方法
CN109563087A (zh) 2016-07-07 2019-04-02 铁木医药有限公司 sGC刺激剂的固体形式
CN109563077B (zh) 2016-07-07 2026-03-10 赛克里翁治疗有限公司 用于制备可溶性鸟苷酸环化酶刺激剂的新方法
MX2020006433A (es) * 2017-12-19 2020-09-17 Cyclerion Therapeutics Inc Estimuladores de guanilato ciclasa soluble (sgc).
US11274096B2 (en) * 2018-01-10 2022-03-15 Cyclerion Therapeutics, Inc. Processes and intermediates for the preparation of soluble guanylate cyclase stimulators

Also Published As

Publication number Publication date
US11773089B2 (en) 2023-10-03
IL263995B (en) 2021-02-28
CN109563077B (zh) 2026-03-10
US20240059684A1 (en) 2024-02-22
CA3029375A1 (en) 2018-01-11
US20220227748A1 (en) 2022-07-21
JP7112384B2 (ja) 2022-08-03
EP3481818B1 (en) 2023-09-06
US11319308B2 (en) 2022-05-03
ES2963563T3 (es) 2024-03-27
EP3481818C0 (en) 2023-09-06
US20210323951A1 (en) 2021-10-21
AU2017291827B2 (en) 2021-10-21
NZ750123A (en) 2025-02-28
KR102487872B1 (ko) 2023-01-12
MX389920B (es) 2025-03-20
IL263995A (en) 2019-02-28
CN121673266A (zh) 2026-03-17
EP4249488A2 (en) 2023-09-27
KR20190025986A (ko) 2019-03-12
MA45603A (fr) 2019-05-15
EP4249488A3 (en) 2023-12-20
EP3481818A1 (en) 2019-05-15
CN109563077A (zh) 2019-04-02
CL2019000016A1 (es) 2019-05-03
WO2018009597A1 (en) 2018-01-11
BR112019000291A2 (pt) 2019-04-16
JP2019525913A (ja) 2019-09-12
MX2022001495A (es) 2022-03-11
MX2019000105A (es) 2019-04-22
EA201990237A1 (ru) 2019-08-30
CL2023000228A1 (es) 2023-09-29
US20260103457A1 (en) 2026-04-16
AU2017291827A1 (en) 2019-02-07

Similar Documents

Publication Publication Date Title
SG11201900633XA (en) Piperidine cxcr7 receptor modulators
SG11201806583XA (en) Compositions containing tucaresol or its analogs
SG11201809559UA (en) Substituted pyridines as inhibitors of dnmt1
SG11201804170RA (en) Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201903908PA (en) Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201903487SA (en) PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF
SG11201907544VA (en) Jak inhibitors containing a 4-membered heterocyclic amide
SG11201805380YA (en) Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapy
SG11201907889YA (en) Glycan-interacting compounds and methods of use
SG11201805514VA (en) Processes for the preparation of 2,5-furandicarboxylic acid and intermediates and derivatives thereof
SG11201909011PA (en) Niraparib compositions
SG11201407533SA (en) Antiviral compounds
SG11201809497RA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201909807TA (en) Methods of manufacturing of niraparib
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201805387RA (en) Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists
SG11201806267QA (en) Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose
SG11201807949WA (en) Engineered immunoglobulins with altered fcrn binding
SG11201805595TA (en) Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1h-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid
SG11201407337QA (en) Cyclodextrin complexation methods for formulating peptide proteasome inhibitors
SG11201900096QA (en) Novel processes for preparation of soluble guanylate cyclase stimulators